Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Ovarian Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × fosbretabulin × Clear all
NCT02055690 2021-05-17

PAZOFOS

The Christie NHS Foundation Trust

Phase 1/2 Terminated
21 enrolled
Gynecologic

Ovarian Neoplasms

NCT00077103 2010-06-11

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Case Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡